Previous 10 | Next 10 |
BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). The two PROTECTOR Phase 3 trials are ...
BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that company management will participate in two in...
BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the initiation of a Phase 1b/2a trial of RTB101, i...
resTORbio ( TORC +1.6% ) announced the closing of its previously announced underwritten public offering of 7.2M shares of its common stock at a public offering price of $6.95/share. More news on: resTORbio, Inc., Read more ...
BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today an...
Motif Bio plc (NASDAQ: MTFB ) +55% on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...
ResTORbio (NASDAQ: TORC ) prices a public offering of 7.2M common stock at a price of $6.95/share for gross proceeds of ~$50M. More news on: resTORbio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today an...
Gainers: Vaxart (NASDAQ: VXRT ) +108% . Sorrento Therapeutics (NASDAQ: SRNE ) +34% . Conformis (NASDAQ: CFMS ) +23% . Blucora (NASDAQ: BCOR ) +20% . StoneCo (NASDAQ: STNE ) +19% . Realm Therapeutics ( RLM ) +19% . Iterum Therapeutics (NASDAQ: ITRM ) +18% . Altimmune (NASDAQ: A...
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has commenc...
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...